Castle Biosciences Announces Second Quarter 2020 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/28/2026
- Nasdaq, S&P 500 lifted by Nvidia's forecast; investors eye speech by Fed's Warsh
- Nvidia forecasts 70% sales growth next year, signals AI spending boom has years left to run
- Oil settles up 2% after Trump rejects return to Iran ceasefire deal terms
- Could SpaceX's orbital compute avoid the political headwinds facing data centers?
- Could Meta's teen settlement be less painful than feared? Citi weighs in
- First Financial to acquire Hickory Point Bank in $111.3M deal
- Affirm Holdings (AFRM) Tops Q4 EPS by $3.77, Beats on Revenue
- Nasdaq, S&P 500 lifted by Nvidia's forecast; investors eye speech by Fed's Warsh
- Ovintiv adds 41,000 acres in Permian and Montney deals
- Rubrik (RBRK) Tops Q2 EPS by 16c, Beats on Revenue; Offers FY27 EPS Guidance
Castle Biosciences Inc. (CSTL) Tops Q2 EPS by 32c
August 10, 2020 4:57 PM EDTCastle Biosciences Inc. (NASDAQ: CSTL) reported Q2 EPS of ($0.08), $0.32 better than the analyst estimate of ($0.40). Revenue for the quarter came in at $12.7 million versus the consensus estimate of $8.8 million.
For earnings history and earnings-related data on Castle Biosciences Inc. (CSTL) click here.
... More